![Kirsty McCarthy](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Kirsty McCarthy active positions
Companies | Position | Start | End |
---|---|---|---|
Pathios Therapeutics Ltd.
![]() Pathios Therapeutics Ltd. BiotechnologyHealth Technology Pathios Therapeutics Ltd. engages in discovering and developing novel small molecule drugs. The company was founded by Thomas David McCarthy, Alan Naylor, Kirsty McCarthy, Peter Joyce and Someit Sidhu in 2017 and is headquartered in Oxford, the United Kingdom. | Chief Operating Officer | 31/12/2016 | - |
Founder | 31/12/2016 | - | |
Grey Wolf Therapeutics Ltd.
![]() Grey Wolf Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Grey Wolf Therapeutics Ltd. is a biotechnology company, which engages in the drug discovery in immuno-oncology. It targets endoplasmic reticulum aminopeptidases 1 and 2 in the antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells. The company was founded by Thomas D. McCarthy and Peter Joyce and is headquartered in Oxford, the United Kingdom. | Chief Operating Officer | - | - |
Career history of Kirsty McCarthy
Statistics
International
United Kingdom | 3 |
Operational
Chief Operating Officer | 2 |
Founder | 1 |
Sectoral
Health Technology | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 2 |
---|---|
Pathios Therapeutics Ltd.
![]() Pathios Therapeutics Ltd. BiotechnologyHealth Technology Pathios Therapeutics Ltd. engages in discovering and developing novel small molecule drugs. The company was founded by Thomas David McCarthy, Alan Naylor, Kirsty McCarthy, Peter Joyce and Someit Sidhu in 2017 and is headquartered in Oxford, the United Kingdom. | Health Technology |
Grey Wolf Therapeutics Ltd.
![]() Grey Wolf Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Grey Wolf Therapeutics Ltd. is a biotechnology company, which engages in the drug discovery in immuno-oncology. It targets endoplasmic reticulum aminopeptidases 1 and 2 in the antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells. The company was founded by Thomas D. McCarthy and Peter Joyce and is headquartered in Oxford, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Kirsty McCarthy
- Experience